At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PPH VanEck Pharmaceutical ETF
Pre-Mkt 08-20 07:46:33 EDT
117.28
+4.08
+3.60%
盘前117.90
+0.62+0.53%
07:23 EDT
High117.73Low115.00Vol747.64K
Open115.00D1 Closing113.20Amplitude2.41%
Mkt Cap1.02BTradable Cap1.02BTotal Shares8.69M
T/O87.53MT/O Rate8.61%Tradable Shares8.69M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BMO Capital Sticks to Their Buy Rating for Merck & Company (MRK)
TIPRANKS  ·  30 minutes ago
BMO Capital Sticks to Their Buy Rating for Merck & Company (MRK)
Novonesis Expects Results from Weight-Loss Drug Supplement Study in 2027
Reuters  ·  39 minutes ago
Novonesis Expects Results from Weight-Loss Drug Supplement Study in 2027
RBC downgrades Merck on ‘unprecedented valuation’ after vaccine data
TIPRANKS  ·  18:35
RBC downgrades Merck on ‘unprecedented valuation’ after vaccine data
Merck price target raised to $166 from $141 at BofA
TIPRANKS  ·  17:50
Merck price target raised to $166 from $141 at BofA
Merck & Co Inc : RBC Cuts to Sector Perform from Outperform; Raises Target Price to $150 from $142
THOMSON REUTERS  ·  17:34
Merck & Co Inc : RBC Cuts to Sector Perform from Outperform; Raises Target Price to $150 from $142
Morgan Stanley Upgrades Merck & Co. to Overweight From Equalweight, Adjusts PT to $179 From $116
MT Newswires Live  ·  17:25
Morgan Stanley Upgrades Merck & Co. to Overweight From Equalweight, Adjusts PT to $179 From $116
China, Hong Kong Stocks Rise on Healthcare, Tech Advance
Reuters  ·  16:38
China, Hong Kong Stocks Rise on Healthcare, Tech Advance
Health Care Roundup: Market Talk
Dow Jones  ·  16:20
Health Care Roundup: Market Talk
Guotai Asset Management Sees Liquidity Boost Driving China Biotech, Innovation Drug Shares Higher
Reuters  ·  15:14
Guotai Asset Management Sees Liquidity Boost Driving China Biotech, Innovation Drug Shares Higher
7 Growth Stocks Holding up in a Tough Market
Dow Jones  ·  13:45
7 Growth Stocks Holding up in a Tough Market
Gubra H1 FY26 Operating Loss Widens to DKK 122.9 Million; Revenue Drops 95% to DKK 126.3 Million
Reuters  ·  13:32
Gubra H1 FY26 Operating Loss Widens to DKK 122.9 Million; Revenue Drops 95% to DKK 126.3 Million
Merck & Co Inc : Jefferies Raises Target Price to $175 from $152
THOMSON REUTERS  ·  12:09
Merck & Co Inc : Jefferies Raises Target Price to $175 from $152
Henlius Shares Surge Nearly 8% on Strategic Alliance with Sandoz for Up to Ten Biosimilars
Deep News  ·  11:00
Henlius Shares Surge Nearly 8% on Strategic Alliance with Sandoz for Up to Ten Biosimilars
Will Foundayo’s UK GLP‑1 Approval and New R&D Deals Change Eli Lilly's (LLY) Narrative?
Simply Wall St.  ·  09:37
Will Foundayo’s UK GLP‑1 Approval and New R&D Deals Change Eli Lilly's (LLY) Narrative?
Today’s Market Recap：U.S. Treasury Steps In to Stabilize Markets,Stocks Rally, Bitcoin Breaks $70,000, Moderna Surges 180%
TradingKey  ·  08:52
Today’s Market Recap：U.S. Treasury Steps In to Stabilize Markets,Stocks Rally, Bitcoin Breaks $70,000, Moderna Surges 180%
Zoetis Inc. Stock Underperforms Wednesday When Compared to Competitors Despite Daily Gains
Dow Jones  ·  04:57
Zoetis Inc. Stock Underperforms Wednesday When Compared to Competitors Despite Daily Gains
Merck & Co. Inc. Stock Advances 12.6%, Outperforms Peers
Dow Jones  ·  04:33
Merck & Co. Inc. Stock Advances 12.6%, Outperforms Peers
Merck upgraded to Overweight from Equal Weight at Morgan Stanley
TIPRANKS  ·  04:30
Merck upgraded to Overweight from Equal Weight at Morgan Stanley
Moderna's Cancer-Vaccine Breakthrough Drives Broad Biopharma Stock Rally
Dow Jones  ·  04:28
Moderna's Cancer-Vaccine Breakthrough Drives Broad Biopharma Stock Rally
Moderna Shares More than Double on Success of mRNA Cancer Vaccine
Dow Jones  ·  03:49
Moderna Shares More than Double on Success of mRNA Cancer Vaccine

Introduction

Company Name.
VanEck Pharmaceutical ETF
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Issue price:
--